Ep. 2: Practical Guidance for Ribociclib and Abemaciclib in the Adjuvant Setting
Key Points
-
CDK4/6 inhibitors can be initiated several months after radiation without compromising efficacy, allowing for a safer, gradual treatment escalation.
-
Common adverse effects include cytopenias, diarrhea (particularly with abemaciclib), liver toxicity, and QTc prolongation (ribociclib).
-
Dose adjustments, temporary interruptions, and careful monitoring are essential to manage adverse effects while maintaining treatment efficacy.
Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, and Rohit Gosain, MD, of Roswell Park Comprehensive Cancer Center, continued the roundtable on adjuvant therapy for early-stage hormone receptor (HR)–positive breast cancer, focusing on practical clinical considerations for CDK4/6 inhibitors, including timing of initiation after radiation and managing adverse effects. Sara Hurvitz, MD, FACP, of Fred Hutchinson Cancer Center; Sherry Shen, MD, of Memorial Sloan Kettering Cancer Center; and Eleonora Teplinsky, MD, of Valley-Mount Sinai Comprehensive Cancer Care, joined the discussion.
Timing of CDK4/6 Inhibitor Initiation
Dr. Hurvitz emphasized that starting CDK4/6 inhibitors several months after radiation is still appropriate, as these drugs aim to treat microscopic metastatic disease present before diagnosis. Enrollment criteria from key trials allowed initiation up to 12 months from the start of endocrine therapy, similar to monarchE’s 16-month window from surgery, supporting flexibility in treatment timing. This approach helps manage cumulative toxicities from chemotherapy, radiation, ovarian suppression, aromatase inhibitors, and CDK4/6 inhibitors and may reduce the risk of early treatment discontinuation.
Comparing Adverse Effect Profiles: Ribociclib vs Abemaciclib
Dr. Shen reviewed the common adverse effects of both ribociclib and abemaciclib, highlighting cytopenias that require close monitoring. Laboratory monitoring should be performed every 2 weeks for the first 2 months, monthly for the next 2 months, and then as clinically indicated. Diarrhea is particularly common with abemaciclib, affecting more than 80% of patients; dose-escalation strategies may help mitigate toxicity, especially in older patients. Ribociclib-related adverse effects include liver toxicity (about 20% of patients) and QTc prolongation (about 5%), although the lower 400-mg adjuvant dose requires less frequent ECG monitoring than the 600-mg metastatic dose. Drug interactions that prolong QTc must also be considered.
Clinical Pearls for Dose Adjustments
Dr. Teplinsky highlighted practical strategies for managing liver enzyme elevations and other toxicities. Dose reduction or temporary interruption may be necessary, with some patients able to continue therapy at a reduced dose (down to 200 mg). Clinicians should prepare patients for potential transient liver enzyme increases and monitor closely, as these events often resolve over time. To minimize adverse effects, careful attention to potential drug–drug interactions is essential for patients receiving long-term therapy.